Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, The Company’s pipeline includes multiple product candidates developed from its proprietary RAMP drug innovation and prodrug technology engines, using the same clinically validated kinase target. The Company is headquartered in Atlanta with additional offices in Lexington, Massachusetts.

Stock Snapshot

IR Contacts

Headquarters

Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway
Suite 1900
Atlanta, GA 30339
T: 617-936-0184
info@inhibikase.com

Investor Relations

SternIR/Precision Medicine
Alex Lobo
T: 212-698-8802
alex.lobo@sternir.com

Transfer Agent

American Stock Transfer & Trust Company, LLC
T: 800-937-5449
help@astfinancial.com
https://www.astfinancial.com